Showing 1 - 5 results of 5 for search 'Priska Kaufmann', query time: 0.03s Refine Results
  1. 1
    Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

    Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects by Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Gehin, Priska Kaufmann

    Published 2024-03-01
    Get full text
    Article
  2. 2
    Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

    Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in health... by Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse

    Published 2023-10-01
    Get full text
    Article
  3. 3
    Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

    Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo by Marion Anliker‐Ort, Jasper Dingemanse, Stephane Delahaye, Luboš Janů, John van denAnker, Benjamin Berger, Priska Kaufmann

    Published 2023-07-01
    Get full text
    Article
  4. 4
    Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

    Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway by Marion Anliker-Ort, Marion Anliker-Ort, Jasper Dingemanse, John van den Anker, John van den Anker, Priska Kaufmann

    Published 2020-12-01
    Get full text
    Article
  5. 5
    Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

    Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist by Marion Anliker‐Ort, Chih‐hsuan Hsin, Andreas Krause, Marc Pfister, John van denAnker, Jasper Dingemanse, Priska Kaufmann

    Published 2023-08-01
    Get full text
    Article

Search Tools: